Decrease in a markedly elevated CA19-9 level after stenting of a benign pancreatic ductal stricture

Mauer, Kenneth; Lopatin, Richard N.; Hoffman, William A.; Grossman, Edward T.; Russo, R

doi:10.1016/s0016-5107(95)70103-6

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As we already described in the Introduction above, a number of previous studies support that GFAP is correlated to specific conditions in patients with various neurodegenerative diseases ( 11 – 15 , 18 , 19 , 30 ). Additionally, GFAP levels considerably increased in CSF from patients suffering from Alexander disease ( 30 ), a genetic disorder caused by mutations in the GFAP gene, leading to myelin abnormalities in the midbrain and cerebellum ( 31 ). These studies support the idea that GFAP could be classified as a diagnostic biomarker in patients with neurological disease conditions.…”

Section: Discussionmentioning

confidence: 99%

Blood Level of Glial Fibrillary Acidic Protein (GFAP) Does not Correlate With Disease Progression in a Rat Model of Familial ALS (SOD1G93A Transgenic)

2018

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by specific loss of motor neurons in the spinal cord and brain stem. Currently, there are limited options for treating ALS and further investigation of the disease etiology and ALS disease progression need to be completed. There is an urgent need to identify biomarkers to detect and study disease progression in ALS. Glial fibrillary acidic protein (GFAP) is an intermediate filament protein that is expressed by a number of cells related to the central nervous system including glial cells and ependymal cells. Recent studies indicated that significant levels of GFAP protein were detected in peripheral tissues, such as skeletal muscle. In this study, we hypothesized that levels of GFAP in blood represent a biomarker of disease progression in ALS. To test this specific hypothesis, we used a rat model of familial ALS (SOD1G93A transgenic), which has been extensively used to understand the complexity of this devastating disease. Disease progression in a cohort of male and female SOD1G93A transgenic rats was monitored by motor function, and blood samples were collected when these animals reached disease end-stage. We measured GFAP protein levels by ELISA and found no correlation between GFAP concentration and disease progression in either serum and plasma samples of SOD1G93A transgenic. Further investigation would be required in order to implicate blood GFAP as a potential biomarker for ALS.

show abstract